All In Biotech

Drug Trial Radar · NCT06542250

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

Sep 18, 2024

Primary completion

Dec 18, 2029

Study completion Dec 18, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

Conditions

  • B-cell Malignancies

Interventions

  • AZD5492Drug

    CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of dose limiting toxicities (DLTs).Time frame: Module 1 - From the first administration of AZD5492 until the end of cycle 1 (up to 5 weeks).
  2. Safety evaluation of AZD5492: Number of participants with treatment-related adverse events.Time frame: Module 1 - From the first administration of AZD5492 within the duration of the treatment period, up to and including 90 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy.
  3. Tolerability evaluation of AZD5492: Number of participants with treatment-related adverse events.Time frame: Module 1 - From the first administration of AZD5492 within the duration of the treatment period, up to and including 90 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy.

Locations

31 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Winston-Salem, North Carolina · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    København Ø, Denmark · Recruiting

  • Research Site

    Pessac, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Göttingen, Germany · Recruiting

  • Research Site

    München, Germany · Recruiting

  • Research Site

    Ulm, Germany · Recruiting

  • Research Site

    Würzburg, Germany · Recruiting

  • Research Site

    Bologna, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    L'Hospitalet de Llobregat, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.